Risks of Investing in Cannabis Stocks

Cannabis stocks carry a unique set of risks that investors must understand before committing capital. While the industry offers significant growth potential, the risk profile is substantially higher than most other sectors.

Regulatory risk is the most significant factor. In the US, cannabis remains a Schedule I controlled substance at the federal level, creating a fundamental conflict between state and federal law. Changes in enforcement policy, rescheduling delays, or the failure of federal reform legislation can cause dramatic stock price swings. Even positive regulatory developments often take longer than expected, frustrating investors who buy on speculation.

Section 280E taxation creates an enormous financial burden for US cannabis companies, as described in our 280E guide. Effective tax rates of 50-80% make profitability extremely difficult and drain cash that could otherwise be reinvested in growth. While rescheduling could eliminate 280E, the timing remains uncertain.

Share dilution is pervasive in the cannabis industry. Many companies fund operations and acquisitions by issuing new shares, warrants, and convertible notes, which dilute existing shareholders. Some cannabis companies have diluted their share count by 50% or more over several years. Always check a company's share count trend and outstanding warrants before investing.

Cash burn and balance sheet risk affect many cannabis operators. High capital expenditure requirements, 280E taxes, and intense competition mean that many companies burn through cash quickly. Evaluate a company's cash runway — how many months of operations their current cash can fund — as a key risk metric.

Market-specific risks include illicit market competition (especially in Canada and states with high tax rates), oversupply driving down wholesale prices, and the fragmented US regulatory landscape that increases compliance costs. Cannabis stocks also tend to be highly correlated with each other and with cannabis reform sentiment, limiting diversification benefits within the sector.

Liquidity risk applies particularly to OTC-traded MSOs, where lower trading volumes can lead to wider bid-ask spreads and difficulty exiting large positions. Institutional ownership is limited due to federal prohibition, further reducing liquidity and price support.